The Expression and Significance of Serum Protein ROCK2 in Patients with Chronic Graft-Versus-Host Disease.
10.19746/j.cnki.issn.1009-2137.2021.05.037
- Author:
Ping TANG
1
;
Chen-Hui ZHENG
1
;
Zhen-Kun DONG
2
;
Meng-Han XIE
1
;
Xin-Sheng XIE
1
;
Hui SUN
1
;
Ling SUN
1
;
Ding-Ming WAN
1
;
Yan-Fang LIU
1
;
Zhong-Xing JIANG
1
;
Rong GUO
3
Author Information
1. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
2. Department of Hematology, The First Affiliated Hospital of Xinxiang University, Xinxiang 453000, Henan Province, China.
3. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China,E-mail: gh7311@aliyun.com.
- Publication Type:Journal Article
- MeSH:
Blood Proteins;
Chronic Disease;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Transplantation, Homologous;
rho-Associated Kinases
- From:
Journal of Experimental Hematology
2021;29(5):1606-1609
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression and clinical significance of serum protein ROCK2 in patients with chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODS:The patients were divided into cGVHD group and control group (without cGVHD). The expression levels of serum protein ROCK2 were detected by ELISA in patients with or without cGVHD after allo-HSCT.
RESULTS:The expression level of ROCK2 in serum of cGVHD patients was significantly higher than those in control group, moreover, the expression level of ROCK2 in severe cGVHD group was significant higher than that in moderate and mild cGVHD group (P<0.001). The expression level of ROCK2 was significantly decreased in the serum of cGVHD patients after treatment（P＜0.01）; the expression level of ROCK2 was significantly higher in the serum of cGVHD patients with lung as the target organ（P＜0.01）. The median survival time of patients with severe cGVHD were significantly shorter than that of patients with mild and moderate cGVHD（P＜0.05）.
CONCLUSION:ROCK2 shows certain reference value in the evaluation of severity and prognosis of cGVHD, and may be a new target for the treatment of cGVHD.
